HPV16 vaccine shows promise in treating precancerous cervical lesions
- A therapeutic vaccine targeting Human Papillomavirus type 16 showed effectiveness in treating high-grade precancerous cervical lesions, as reported in a Phase II clinical trial published in Clinical Cancer Research.
- In the trial, 18 patients with HPV16-positive cervical intraepithelial neoplasia grade 3 received three doses of the vaccine VVax001, resulting in regression in nine patients, including three with complete regression.
- The study demonstrated that 10 of 16 patients evaluated cleared HPV16, and after a median follow-up of 20 months, none of the patients had recurrences, according to the authors.
- The findings suggest that VVax001 could be a non-invasive alternative to the standard loop excision treatment, which is associated with complications, stated Refika Yigit, MD.
Insights by Ground AI
Does this summary seem wrong?
Coverage Details
Total News Sources0
Leaning Left0Leaning Right1Center3Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
C 75%
R 25%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
